Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,809 GBX | -0.50% |
|
-3.11% | +1.12% |
24/06 | Teva launches generic version of Novo Nordisk's diabetes drug Victoza | RE |
20/06 | Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position' | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.12% | 5.17B | |
+57.66% | 823B | |
-6.85% | 353B | |
+15.48% | 320B | |
+7.65% | 295B | |
+13.62% | 239B | |
+14.55% | 220B | |
-0.33% | 219B | |
+8.23% | 167B | |
-2.90% | 159B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Transcript : Hikma Pharmaceuticals PLC, 2016 Earnings Call, Mar 15, 2017